Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

	Initial disclosure (complete Parts A, B, C, D, F, and G of this notice)	Ongoing disclosure (complete A, B, C, E, F, and G of this not	
Preliminary			
1.	Name	Dr John Douglas Wilson	
2.	Name of issuer	Neuren Pharmaceuticals Limited	
3.	Name of related body corporate (if applicable)	Ridgefield Family Trust	
4.	Position you hold in the issuer	Director	
5.	Date of this disclosure notice	14 March 2005	
Natu 6.	Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b))	Ridgefield Family Trust	
7.	Class and type of security (as required by regulation 6B or regulation 8)	Ordinary Shares	
8.	Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))	Relevant interest as a trustee of the Ridgefield Family Trust	
Date	e (for initial disclosure) Date of disclosure obligation (as	N/A	
	required by regulation 6C)		
Tran	saction (for ongoing disclosure)		
10.	Date of last disclosure (as required by regulation 13)	N/A	
11.	Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)	4 February 2005	
12.	Number of transactions (as required by regulation 12(2), if applicable)	135,000	
13.	Nature or type of transaction (as required by regulation 11(1)(a))	Ordinary Shares	
14.	Consideration (as required by regulation 10)	A\$50,000	

15.	Number of securities held prior, set out by class and type (as required by regulation 8)	NIL
16.	Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b))	NIL

F. Extent of relevant interest

Ī	17.	Number of securities held now, set out	135,000 Ordinary Shares
		by class and type (as required by	
		regulation 6B or regulation 8)	

G. Signature

18.	Signature (as required by regulation 14)	

Disclosure of Directors' and Officer's Relevant Interests

Section 19T, Securities Markets Act 1988

	Initial disclosure (complete Parts A, B, C, D, F, and G of this notice)	✓	Ongoing disclosure (complete Pa A, B, C, E, F, and G of this notice)	
Preliminary				
1.	Name	Mr Grae	eme Howie	
2.	Name of issuer	Neuren	Pharmaceuticals Limited	
3.	Name of related body corporate (if applicable)	N/A		
4.	Position you hold in the issuer	Director	r	
5.	Date of this disclosure notice	14 Marc	ch 2005	
6.	Name of registered holder(s) of security (as requested by regulation 6A(b) or regulation 7(b))	Mr Grae	eme Howie	
6.	(as requested by regulation 6A(b) or	Mr Grae	eme Howie	
7.	by regulation 6B or regulation 8)		y Shares	
8.	Nature of relevant interest in security (as required by regulation 6A(a) or regulation 7(a))		nt interest as director of Neuren ceuticals Limited	
Da	Date of disclosure obligation (as required by regulation 6C)	N/A		
Tra	unsaction (for ongoing disclosure)			
10	Date of last disclosure (as required by regulation 13)	N/A		
11	Date(s) of acquisition(s) or disposal(s) (as required by regulation 9)	4 March	1 2005	
12	Number of transactions (as required by regulation 12(2), if applicable)		Ordinary Shares	
13	B. Nature or type of transaction (as required by regulation 11(1)(a))	Ordinar	y Shares	
<u></u>	required by regulation TT(T)(a))			

10)

15.	Number of securities held prior, set out by class and type (as required by regulation 8)	
16.	Number of securities subject to acquisition or disposal (as required by regulation 11(1)(b))	NIL

F. Extent of relevant interest

17.	Number of securities held now, set out	50,000 Ordinary Shares
	by class and type (as required by	
	regulation 6B or regulation 8)	

G. Signature

18.	Signature (as required by regulation 14)	